VITAMIN D RECEPTOR (VDR) AND VITAMIN D LEVELS IN LEUKEMIA AND LYMPHOMA PATIENTS
INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY · 13.03.2026 · 32 (2) · 228-234
DOI: 10.24293/ijcpml.v32i2.2487 ↗Kurz gefasst
Fachartikel in der Zeitschrift INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY, online erschienen am 13.03.2026. Verfasst von Anggraini Iriani und 6 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-SA 4.0).
Abstract (Originalsprache)
In leukemia and lymphoma, vitamin D exerts anti-tumor effects mediated by its binding to the vitamin D receptor (VDR). Vitamin D is related to cancer prognosis and response to therapy. However, the prevalence of vitamin D deficiency remains significantly high among the Indonesian population. This study aims to determine the profile of vitamin D and vitamin D receptor (VDR) levels in leukemia and lymphoma patients. This study design was a cross-sectional with a comparative analysis of vitamin D and its receptors, conducted on adult leukemia-lymphoma patients and control samples. Vitamin D examination was completed on 180 samples of 123 leukemia and lymphoma patients, and 57 controls. Vitamin D receptor (VDR) examination was conducted on 45 leukemia and lymphoma patients and 57 controls. The prevalence of vitamin D deficiency in the leukemia and lymphoma group was 85.4%. Subgroup analysis revealed that the prevalence of vitamin D deficiency was significantly higher in leukemia and lymphoma patients aged ≤40 years compared to their respective control group (p =0.039). There was no significant vitamin D receptor level between leukemia and lymphoma and the control group based on all age groups, male, and vitamin D status. Vitamin D receptor level was 0.53 (0.19) ng/mL in leukemia and lymphoma females, lower than the control group 0.73 (0.73) ng/mL, significantly. This study concluded that leukemia and lymphoma patients predominantly have vitamin D deficiency. Vitamin D receptor level is lower in females with leukemia and lymphoma than in the normal population. Vitamin D receptor can be considered as an adjunct marker in assessing vitamin D status in leukemia lymphoma cases.
Zitieren
APA
Iriani, A., Rachman, A., Fatina, M. K., Muskananfola, F. V., Nugraha, M. F. I., Gemilang, R. K., & Trisnandi, A. (2026). VITAMIN D RECEPTOR (VDR) AND VITAMIN D LEVELS IN LEUKEMIA AND LYMPHOMA PATIENTS. INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY, 32(2), 228-234. https://doi.org/10.24293/ijcpml.v32i2.2487
Vancouver
Iriani A, Rachman A, Fatina MK, Muskananfola FV, Nugraha MFI, Gemilang RK, et al. VITAMIN D RECEPTOR (VDR) AND VITAMIN D LEVELS IN LEUKEMIA AND LYMPHOMA PATIENTS. INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY. 2026;32(2):228-234. doi:10.24293/ijcpml.v32i2.2487
BibTeX
@article{Iriani2026,
author = {Iriani, Anggraini and Rachman, Andhika and Fatina, Marsya Kaila and Muskananfola, Fiona Valerie and Nugraha, Media Fitri Isma and Gemilang, Rizka Kurnia and Trisnandi, Andi},
title = {VITAMIN D RECEPTOR (VDR) AND VITAMIN D LEVELS IN LEUKEMIA AND LYMPHOMA PATIENTS},
journal = {INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY},
year = {2026},
volume = {32},
number = {2},
pages = {228--234},
doi = {10.24293/ijcpml.v32i2.2487}
}
EUVIMED